Table 2.
Medical History of Belarusian Healthcare Professionals Participating in the mpox Survey, October 2022, (n = 144).
| Variable | Outcome | Mpox VAX Rejection (n = 26) |
Mpox VAX Hesitancy (n = 44) |
Mpox VAX Acceptance (n = 74) |
Total (n = 144) |
p. |
|---|---|---|---|---|---|---|
| Chronic Diseases |
Bowel Disease | 5 (19.2%) | 6 (13.6%) | 10 (13.5%) | 21 (14.6%) | 0.773 |
| Thyroid Disease | 3 (11.5%) | 5 (11.4%) | 9 (12.2%) | 17 (11.8%) | 1.000 | |
| Ophthalmologic Disease | 1 (3.8%) | 4 (9.1%) | 8 (10.8%) | 13 (9%) | 0.680 | |
| Allergy | 2 (7.7%) | 2 (4.5%) | 7 (9.5%) | 11 (7.6%) | 0.643 | |
| Cardiovascular Disease | 1 (3.8%) | 2 (4.5%) | 5 (6.8%) | 8 (5.6%) | 1.000 | |
| Renal Disorders | 2 (7.7%) | 1 (2.3%) | 4 (5.4%) | 7 (4.9%) | 0.595 | |
| Chronic Hypertension | 2 (7.7%) | 0 (0%) | 3 (4.1%) | 5 (3.5%) | 0.158 | |
| Neurologic Disease | 2 (7.7%) | 1 (2.3%) | 0 (0%) | 3 (2.1%) | 0.062 | |
| Blood Disease | 0 (0%) | 1 (2.3%) | 1 (1.4%) | 2 (1.4%) | 1.000 | |
| Cancer | 0 (0%) | 0 (0%) | 2 (2.7%) | 2 (1.4%) | 0.684 | |
| Rheumatoid Arthritis | 1 (3.8%) | 1 (2.3%) | 0 (0%) | 2 (1.4%) | 0.235 | |
| Asthma | 0 (0%) | 0 (0%) | 1 (1.4%) | 1 (0.7%) | 1.000 | |
| Diabetes Mellitus type-I | 0 (0%) | 0 (0%) | 1 (1.4%) | 1 (0.7%) | 1.000 | |
| Diabetes Mellitus type-II | 1 (3.8%) | 0 (0%) | 0 (0%) | 1 (0.7%) | 0.181 | |
| Hepatologic Disease | 1 (3.8%) | 0 (0%) | 0 (0%) | 1 (0.7%) | 0.181 | |
| Total | 12 (46.2%) | 19 (43.2%) | 29 (39.2%) | 60 (41.7%) | 0.801 | |
| Medications | Thyroid Hormones | 2 (7.7%) | 6 (13.6%) | 3 (4.1%) | 11 (7.6%) | 0.155 |
| Hormonal Drugs | 0 (0%) | 4 (9.1%) | 4 (5.4%) | 8 (5.6%) | 0.297 | |
| Antihypertensives | 1 (3.8%) | 1 (2.3%) | 3 (4.1%) | 5 (3.5%) | 1.000 | |
| Contraceptives | 1 (3.8%) | 1 (2.3%) | 3 (4.1%) | 5 (3.5%) | 1.000 | |
| Antidiabetics | 1 (3.8%) | 1 (2.3%) | 1 (1.4%) | 3 (2.1%) | 0.756 | |
| Antihistamines | 0 (0%) | 1 (2.3%) | 1 (1.4%) | 2 (1.4%) | 1.000 | |
| Immunosuppressives | 1 (3.8%) | 1 (2.3%) | 0 (0%) | 2 (1.4%) | 0.235 | |
| Anticoagulants | 1 (3.8%) | 0 (0%) | 0 (0%) | 1 (0.7%) | 0.181 | |
| NSAIDs | 0 (0%) | 0 (0%) | 1 (1.4%) | 1 (0.7%) | 1.000 | |
| Other Medications | 0 (0%) | 2 (15.4%) | 2 (12.5%) | 4 (12.1%) | 1.000 | |
| Total | 4 (15.4%) | 13 (29.5%) | 16 (21.6%) | 33 (22.9%) | 0.368 | |
| COVID-19 Vaccine | One Dose | 1 (3.8%) | 1 (2.3%) | 2 (2.7%) | 4 (2.8%) | 1.000 |
| Two Doses | 5 (19.2%) | 17 (38.6%) | 22 (29.7%) | 44 (30.6%) | 0.229 | |
| Three Doses | 7 (26.9%) | 12 (27.3%) | 23 (31.1%) | 42 (29.2%) | 0.873 | |
| Four Doses | 2 (7.7%) | 9 (20.5%) | 11 (14.9%) | 22 (15.3%) | 0.369 | |
| ≥Five Doses | 1 (3.8%) | 0 (0%) | 3 (4.1%) | 4 (2.8%) | 0.399 | |
| Total | 16 (61.5%) | 39 (88.6%) | 61 (82.4%) | 116 (80.6%) | 0.018 | |
| Flu Vaccine | No | 10 (38.5%) | 10 (22.7%) | 7 (9.5%) | 27 (18.8%) | 0.004 |
| Yes | 16 (61.5%) | 34 (77.3%) | 67 (90.5%) | 117 (81.3%) | ||
| Recent Flu Vaccine | No | 6 (37.5%) | 13 (38.2%) | 30 (44.8%) | 49 (41.9%) | 0.762 |
| Yes | 10 (62.5%) | 21 (61.8%) | 37 (55.2%) | 68 (58.1%) | ||
| Smallpox Vaccine | No | 19 (73.1%) | 34 (77.3%) | 64 (86.5%) | 117 (81.3%) | 0.199 |
| Yes | 7 (26.9%) | 10 (22.7%) | 10 (13.5%) | 27 (18.8%) |
The Chi-squared test (χ2) and Fisher’s exact test were used with a significance level (p.) ≤ 0.05.